Welcome to Markets Desk, here's what's moving the conversation today.
In the AI infrastructure space, investors are weighing two very different bets. IREN brings secured power capacity to the table, a genuinely scarce asset in the data center buildout, but dilution risk remains a real concern. Nebius, meanwhile, has locked in hyperscaler contracts that signal serious execution credibility, making the valuation debate a tight one.
Shifting to broader equity markets, the Invesco Nasdaq one hundred ETF, ticker QQQM, is sitting roughly seven percent off its recent high, and historically that's been a meaningful entry signal. The fund has delivered around fourteen percent in average annual returns since inception, and pullbacks of this magnitude have repeatedly rewarded patient, long-horizon buyers.
On the pharmaceutical side, AbbVie continues to draw Wall Street conviction, and the reason is straightforward. The company inherited its Dividend King status through its Abbott spinoff but has since earned it independently, sustaining and growing its payout through pipeline transitions that would have rattled lesser balance sheets. Analysts see that discipline holding.
That's the tape. Markets Desk, signing off the floor.
